Jones DS - Search Results

1

Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity.

O'Rourke AM, Wang EY, Miller A, Podar EM, Scheyhing K, Huang L, Kessler C, Gao H, Ton-Nu HT, Macdonald MT, Jones DS, Linnik MD. O'Rourke AM, et al. Among authors: jones ds. J Pharmacol Exp Ther. 2008 Feb;324(2):867-75. doi: 10.1124/jpet.107.131672. Epub 2007 Nov 9. J Pharmacol Exp Ther. 2008. PMID: 17993604

2

Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis.

O'Rourke AM, Wang EY, Salter-Cid L, Huang L, Miller A, Podar E, Gao HF, Jones DS, Linnik MD. O'Rourke AM, et al. Among authors: jones ds. J Neural Transm (Vienna). 2007;114(6):845-9. doi: 10.1007/s00702-007-0699-3. Epub 2007 Mar 29. J Neural Transm (Vienna). 2007. PMID: 17393060

3

Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of beta2GPI and suppression of an anti-beta2GPI immune response.

Jones DS, Cockerill KA, Gamino CA, Hammaker JR, Hayag MS, Iverson GM, Linnik MD, McNeeley PA, Tedder ME, Ton-Nu HT, Victoria EJ. Jones DS, et al. Bioconjug Chem. 2001 Nov-Dec;12(6):1012-20. doi: 10.1021/bc015512x. Bioconjug Chem. 2001. PMID: 11716694

4

Pharmacokinetics of LJP 993, a tetrameric conjugate of domain 1 of beta2-glycoprotein I for antiphospholipid syndrome.

Jia L, Gu Y, Zeng E, Linnik MD, Jones DS. Jia L, et al. Among authors: jones ds. Lupus. 2010 Feb;19(2):130-7. doi: 10.1177/0961203309348982. Epub 2009 Nov 17. Lupus. 2010. PMID: 19919973 Free PMC article.

5

Therapeutic potential of toleragens in the management of antiphospholipid syndrome.

Cockerill KA, Iverson GM, Jones DS, Linnik MD. Cockerill KA, et al. Among authors: jones ds. BioDrugs. 2004;18(5):297-305. doi: 10.2165/00063030-200418050-00002. BioDrugs. 2004. PMID: 15377172 Review.

6

A chemically defined, toleragen-based approach for targeting anti-beta2-glycoprotein I antibodies.

Iverson GM, Jones DS, Marquis D, Linnik MD, Victoria EJ. Iverson GM, et al. Among authors: jones ds. Lupus. 1998;7 Suppl 2:S166-9. doi: 10.1177/096120339800700236. Lupus. 1998. PMID: 9814697

7

Multivalent poly(ethylene glycol)-containing conjugates for in vivo antibody suppression.

Jones DS, Branks MJ, Campbell MA, Cockerill KA, Hammaker JR, Kessler CA, Smith EM, Tao A, Ton-Nu HT, Xu T. Jones DS, et al. Bioconjug Chem. 2003 Nov-Dec;14(6):1067-76. doi: 10.1021/bc034103t. Bioconjug Chem. 2003. PMID: 14624619

8

Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response.

Jones DS, Coutts SM, Gamino CA, Iverson GM, Linnik MD, Randow ME, Ton-Nu HT, Victoria EJ. Jones DS, et al. Bioconjug Chem. 1999 May-Jun;10(3):480-8. doi: 10.1021/bc9801373. Bioconjug Chem. 1999. PMID: 10346881

9

In vivo characterization of bioconjugate B cell toleragens with specificity for autoantibodies in antiphospholipid syndrome.

Cockerill KA, Smith E, Jones DS, Branks MJ, Hayag M, Victoria EJ, Linnik MD, Campbell MA. Cockerill KA, et al. Among authors: jones ds. Int Immunopharmacol. 2003 Nov;3(12):1667-75. doi: 10.1016/S1567-5769(03)00203-0. Int Immunopharmacol. 2003. PMID: 14555291

10

Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis.

Jones DS, Barstad PA, Feild MJ, Hachmann JP, Hayag MS, Hill KW, Iverson GM, Livingston DA, Palanki MS, Tibbetts AR, et al. Jones DS, et al. J Med Chem. 1995 Jun 9;38(12):2138-44. doi: 10.1021/jm00012a013. J Med Chem. 1995. PMID: 7783145

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

512 results

Search Page

Filters